We compared EUCAST and CLSI antifungal susceptibility testing methods for itraconazole, posaconazole, and voriconazole by testing 245 Aspergillus clinical isolates. The essential agreement (EA) between methods was excellent: 100% (itraconazole), 98.4% (posaconazole), and 99.6% (voriconazole) assessing EA at ؎2 dilutions and 99.6% (itraconazole), 87.7% (posaconazole), and 96.3% (voriconazole) at ؎1 dilution.The triazole antifungals include the mold-active agents itraconazole, posaconazole, and voriconazole (2). Each of these agents has good in vitro and in vivo activity against most species of Aspergillus (1,9,12,16,17,22,29). Although resistance (R) to triazoles is uncommon, increased R has been noted in several regions of the world since 1999 (11,12,23,25,27,28). These observations suggest that triazole resistance among Aspergillus spp. may be more common than acknowledged and that clinical microbiology laboratories should determine the in vitro susceptibility of clinically relevant isolates of Aspergillus spp. (9,11,12,17,22,28).There are two independent standards for broth microdilution (BMD) antifungal susceptibility testing of triazole activity against Aspergillus species: the Clinical and Laboratory Standards Institute (CLSI) method (5) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) method (7,13,15,24). The two methods are similar in that both use BMD, RPMI 1640 broth, incubation at 35 to 37°C for 48 h, and a complete (100%) inhibition visual MIC endpoint. In an effort to further pursue the harmonization of the CLSI and EUCAST BMD methods for testing the triazoles and Aspergillus spp., we have utilized our 2009 global antifungal surveillance database (18,19) to determine the EA between the CLSI and EUCAST MICs for 245 clinical isolates of Aspergillus species tested against itraconazole, posaconazole, and voriconazole. This report represents the most extensive comparison of these two BMD methods for the testing of Aspergillus spp. to date. Given the important role that both methods currently play in antifungal resistance surveillance, it is important to demonstrate the comparability of the results (11, 14-17, 22, 28).A total of 245 clinical isolates of Aspergillus spp. obtained from 20 medical centers worldwide during 2009 were tested against itraconazole, posaconazole, and voriconazole. The collection included 160 isolates of A. fumigatus, 32 of A. flavus, 40 of A. niger, and 13 of miscellaneous species, including 8 of A. terreus, 3 of A. versicolor, and 1 each of A. nidulans and A. glaucus. The isolates were obtained from a variety of sources, including sputum, bronchoscopy, and tissue biopsy specimens, and represented individual infectious episodes. The isolates were collected at individual study sites and sent to the University of Iowa (Iowa City) for identification and susceptibility testing as described previously (17, 18). All isolates were identified by standard microscopic morphology (26) and were stored as spore suspensions in sterile distilled water at room temperatu...